vs

Side-by-side financial comparison of American Express (AXP) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $18.9M, roughly 1.5× American Express). American Express runs the higher net margin — 15.7% vs -71.0%, a 86.7% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 11.4%).

American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

AXP vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.5× larger
ZYME
$27.6M
$18.9M
AXP
Growing faster (revenue YoY)
ZYME
ZYME
+61.2% gap
ZYME
72.6%
11.4%
AXP
Higher net margin
AXP
AXP
86.7% more per $
AXP
15.7%
-71.0%
ZYME

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
AXP
AXP
ZYME
ZYME
Revenue
$18.9M
$27.6M
Net Profit
$3.0M
$-19.6M
Gross Margin
Operating Margin
-80.1%
Net Margin
15.7%
-71.0%
Revenue YoY
11.4%
72.6%
Net Profit YoY
15.0%
34.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXP
AXP
ZYME
ZYME
Q1 26
$18.9M
Q4 25
$10.9B
Q3 25
$10.4B
$27.6M
Q2 25
$10.3B
$48.7M
Q1 25
$9.6B
$27.1M
Q4 24
$10.0B
$31.0M
Q3 24
$9.7B
$16.0M
Q2 24
$9.8B
$19.2M
Net Profit
AXP
AXP
ZYME
ZYME
Q1 26
$3.0M
Q4 25
$2.5B
Q3 25
$2.9B
$-19.6M
Q2 25
$2.9B
$2.3M
Q1 25
$2.6B
$-22.6M
Q4 24
$2.2B
$-23.5M
Q3 24
$2.5B
$-29.9M
Q2 24
$3.0B
$-37.7M
Operating Margin
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
28.2%
Q3 25
36.7%
-80.1%
Q2 25
34.4%
-1.4%
Q1 25
34.6%
-94.5%
Q4 24
27.7%
-71.6%
Q3 24
33.0%
-213.8%
Q2 24
38.6%
-222.9%
Net Margin
AXP
AXP
ZYME
ZYME
Q1 26
15.7%
Q4 25
22.5%
Q3 25
27.9%
-71.0%
Q2 25
28.0%
4.8%
Q1 25
26.8%
-83.5%
Q4 24
21.8%
-75.8%
Q3 24
25.8%
-186.6%
Q2 24
30.7%
-195.8%
EPS (diluted)
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
$3.52
Q3 25
$4.14
$-0.26
Q2 25
$4.08
$0.03
Q1 25
$3.64
$-0.30
Q4 24
$3.04
$-0.32
Q3 24
$3.49
$-0.39
Q2 24
$4.15
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXP
AXP
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$64.8M
Total DebtLower is stronger
$60.4M
Stockholders' EquityBook value
$34.0M
$320.1M
Total Assets
$308.9M
$397.3M
Debt / EquityLower = less leverage
1.78×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
$742.0M
Q3 25
$1.3B
$64.8M
Q2 25
$197.0M
$98.3M
Q1 25
$261.0M
$76.2M
Q4 24
$221.0M
$66.1M
Q3 24
$120.0M
$122.4M
Q2 24
$188.0M
$71.0M
Total Debt
AXP
AXP
ZYME
ZYME
Q1 26
$60.4M
Q4 25
$56.4B
Q3 25
$57.8B
Q2 25
$58.2B
Q1 25
$51.2B
Q4 24
$49.7B
Q3 24
$53.5B
Q2 24
$51.5B
Stockholders' Equity
AXP
AXP
ZYME
ZYME
Q1 26
$34.0M
Q4 25
$33.5B
Q3 25
$32.4B
$320.1M
Q2 25
$32.3B
$334.5M
Q1 25
$31.2B
$325.0M
Q4 24
$30.3B
$338.8M
Q3 24
$29.7B
$367.0M
Q2 24
$29.5B
$406.2M
Total Assets
AXP
AXP
ZYME
ZYME
Q1 26
$308.9M
Q4 25
$300.1B
Q3 25
$297.6B
$397.3M
Q2 25
$295.6B
$408.4M
Q1 25
$282.2B
$425.5M
Q4 24
$271.5B
$463.1M
Q3 24
$271.0B
$487.2M
Q2 24
$272.2B
$515.6M
Debt / Equity
AXP
AXP
ZYME
ZYME
Q1 26
1.78×
Q4 25
1.68×
Q3 25
1.78×
Q2 25
1.80×
Q1 25
1.64×
Q4 24
1.64×
Q3 24
1.80×
Q2 24
1.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXP
AXP
ZYME
ZYME
Operating Cash FlowLast quarter
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
$3.1B
Q3 25
$6.2B
$-31.4M
Q2 25
$4.4B
$12.1M
Q1 25
$4.8B
$-3.4M
Q4 24
$5.8B
$-41.5M
Q3 24
$-1.8B
$-5.9M
Q2 24
$4.5B
$-25.0M
Free Cash Flow
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
$2.3B
Q3 25
$5.6B
$-31.8M
Q2 25
$3.7B
$11.6M
Q1 25
$4.3B
$-3.4M
Q4 24
$5.3B
$-41.8M
Q3 24
$-2.3B
$-6.8M
Q2 24
$4.0B
$-25.6M
FCF Margin
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
21.4%
Q3 25
53.6%
-115.2%
Q2 25
36.3%
23.7%
Q1 25
45.0%
-12.6%
Q4 24
53.1%
-134.8%
Q3 24
-23.3%
-42.4%
Q2 24
40.4%
-133.0%
Capex Intensity
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
6.6%
Q3 25
6.3%
1.5%
Q2 25
6.0%
1.1%
Q1 25
4.5%
0.1%
Q4 24
5.0%
1.0%
Q3 24
4.7%
5.6%
Q2 24
5.8%
3.1%
Cash Conversion
AXP
AXP
ZYME
ZYME
Q1 26
Q4 25
1.25×
Q3 25
2.15×
Q2 25
1.51×
5.21×
Q1 25
1.84×
Q4 24
2.66×
Q3 24
-0.72×
Q2 24
1.50×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXP
AXP

Discount revenue$9.5M50%
Other$8.9M47%
Deposits with banks and other$512.0K3%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons